<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01362179</url>
  </required_header>
  <id_info>
    <org_study_id>LTDFU</org_study_id>
    <nct_id>NCT01362179</nct_id>
  </id_info>
  <brief_title>National Marrow Donor Program Long-Term Donor Follow-Up</brief_title>
  <acronym>LTDFU</acronym>
  <official_title>Incidence of Hematologic and Non-Hematologic Malignancies, Thrombotic Events, and Autoimmune Disorders in Unrelated Normal Donors Undergoing Bone Marrow Harvest Versus Peripheral Blood Stem Cell Mobilization With Recombinant Human Granulocyte Colony-Stimulating Factor (rHuG-CSF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center for International Blood and Marrow Transplant Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Marrow Donor Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Center for International Blood and Marrow Transplant Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational study of unstimulated bone marrow (BM) and filgrastim-mobilized
      peripheral blood stem cell (PBSC) donors. The primary goal is to evaluate the hypothesis that
      the incidence of targeted malignant, thrombotic and autoimmune disorders after unrelated
      hematopoietic stem cell donation are similar between unstimulated BM and filgrastim-mobilized
      PBSC donors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational study of unstimulated bone marrow (BM) and filgrastim-mobilized
      peripheral blood stem cell (PBSC) donors. The primary goal is to evaluate the hypothesis that
      the incidence of targeted malignant, thrombotic and autoimmune disorders after unrelated
      hematopoietic stem cell donation are similar between unstimulated BM and filgrastim-mobilized
      PBSC donors. Donors will undergo biennial surveys until study completion. Cases of targeted
      disorders will be reviewed by the medical monitors to confirm the veracity of the report.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of malignant myeloid hematologic disorders</measure>
    <time_frame>Post HSCT donation</time_frame>
    <description>To describe the long-term incidence of malignant myeloid hematologic disorders in donors who received and in those who did not receive filgrastim.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">21932</enrollment>
  <condition>Hematologic Neoplasms</condition>
  <arm_group>
    <arm_group_label>unstimulated BM donors</arm_group_label>
    <description>Observational (non-interventional) study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>filgrastim-mobilized PBSC donors</arm_group_label>
    <description>Observational (non-interventional) study.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        10,000 unstimulated BM donors and 20,000 filgrastim-mobilized PBSC donors
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Unrelated donor who donated either unstimulated BM or filgrastim-mobilized PBSC
             between July 1, 1999 and approximately five years post study activation.

          2. Unrelated donor who received at least one injection of filgrastim or more, but did not
             donate filgrastim-mobilized PBSC between July 1, 1999 and approximately five years
             post study activation.

          3. Donation was managed by a U.S. NMDP donor center.

          4. Signed informed consent for participation in this long-term donor follow-up study.
             Concurrent enrollment on other studies is permitted.

        Exclusion Criteria:

          1. Unrelated donor who donated filgrastim-mobilized bone marrow.

          2. Donation was managed by a non-U.S. donor center.

          3. Donor is unable to verbally communicate in any of the following languages: English,
             Spanish, Mandarin Chinese, Cantonese Chinese, Vietnamese, Korean, or Portuguese.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John P Miller, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Marrow Donor Program</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Marrow Donor Program Northern California &amp; Northwest District</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Marrow Donor Program Southern California &amp; Southwest District</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Marrow Donor Program</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230-6918</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Blood Centers of Florida, Inc.</name>
      <address>
        <city>Lauderhill</city>
        <state>Florida</state>
        <zip>33313-5006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hawaii Bone Marrow Donor Registry</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96817-1651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LifeSource</name>
      <address>
        <city>Glenview</city>
        <state>Illinois</state>
        <zip>60025-2498</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rock River Valley Blood Center</name>
      <address>
        <city>Rockford</city>
        <state>Illinois</state>
        <zip>61107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Blood Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46208-4437</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Marrow Donor Program Southcentral District, Heart of America</name>
      <address>
        <city>Leawood</city>
        <state>Kansas</state>
        <zip>66206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205-2020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NIH Marrow Donor Center</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20852-3839</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115-6013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Blood</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The HLA Registry</name>
      <address>
        <city>Oradell</city>
        <state>New Jersey</state>
        <zip>07649</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Blood Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DKMS Americas</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Marrow Donor Program Southeast District</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28269</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Marrow Donor Program Northcentral District</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Blood Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104-3251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Marrow Donor Program Northeast District</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19123-3594</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Blood Center</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02908-4811</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blood Assurance, Inc.</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403-1207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cooperative Appalachian Marrow Program Medic Regional Blood Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246-2029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cook Children's</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gulf Coast Regional Blood Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054-1802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Texas Blood and Tissue Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78201-2023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott &amp; White Clinic</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Puget Sound Blood Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104-1239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Blood Center, Inc.</name>
      <address>
        <city>Appleton</city>
        <state>Wisconsin</state>
        <zip>54914-9106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Marrow Donor Program at Puerto Rico</name>
      <address>
        <city>Guaynabo</city>
        <zip>00968-2710</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2011</study_first_submitted>
  <study_first_submitted_qc>May 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2011</study_first_posted>
  <last_update_submitted>June 13, 2017</last_update_submitted>
  <last_update_submitted_qc>June 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>malignant myeloid hematologic disorders</keyword>
  <keyword>filgrastim</keyword>
  <keyword>long term incidence</keyword>
  <keyword>donors who received and in those who did not receive filgrastim.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

